Asset
Trastuzumab Imbotolimod
Bolt Biotherapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04278144 | phase1_2 | terminated | 2020-02-24 | 2024-12-10 | Bolt Biotherapeutics, Inc. | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
| NCT05954143 | phase2 | terminated | 2023-11-30 | 2024-09-20 | Bolt Biotherapeutics, Inc. | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.